LOGO
LOGO

Corporate News

Bill.com Climbs As Quarterly Results, Outlook Better Than Street View

By RTTNews Staff Writer   ✉   | Published:   | Follow Us On Google News
rttnewslogo20mar2024

Shares of cloud-based software provider Bill.com Holdings, Inc. (BILL) are up more than 16% Friday morning at $173.90, after reporting better-than-expected fourth-quarter results. The company's first-quarter as well as full-year outlook also came in above analysts' view.

Bill.com reported net loss of $84.9 million, or $0.81 per share compared with net loss of $41.9 million, or $0.48 per share in the same quarter a year ago.

Excluding one-time items, loss was $3.3 million, or $0.03 per share, that beat the average estimate of analysts polled by Thomson-Reuters of $0.03 loss per share.

Quarterly revenue increased 156% year-on-year to $200.2 million.

Looking forward to the first quarter, the company expects revenue to increase 76%-78% year-over-year to the range of $208 million- $211 billion and adjusted EPS is expected to be in the range of $0.05-$0.07. Analysts expect loss of $0.09 per share on revenue of $187.6 million.

For the full year, Bill.com sees 49%-52% revenue increase to $955.5 million- $973.5 million and adjusted EPS of $0.23-$0.38.
Analysts expect the company to report loss of $0.34 per share on revenue of $879.68 million for the year.

BILL has traded in the range of $89.87-$348.49 in the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Global Economics Weekly Update - April 27 – May 01, 2026

May 01, 2026 15:54 ET
Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.

Latest Updates on COVID-19